文献速递胸部肿瘤

肺腺癌中新获得的EGFR外显子20 M766Q突变介导奥希替尼耐药但对来那替尼和波齐替尼敏感

A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
PubMed 文献 · J Thorac Oncol · 2019-06-27

一例79岁女性EGFR L858R/T790M肺腺癌患者在三线奥希替尼治疗进展后,循环游离DNA测序发现新获得的EGFR外显子20 M766Q突变且T790M消失。同源建模提示M766Q可破坏奥希替尼结合;L858R/M766Q双突变细胞对奥希替尼耐药性为L858R细胞的12倍,对厄洛替尼和阿法替尼耐药性超过250倍,但对来那替尼和波齐替尼仍敏感(IC50分别为4.3和1.3 nM)。

要点

  • EGFR M766Q外显子20突变是奥希替尼获得性耐药的新机制。
  • L858R/M766Q双突变细胞对奥希替尼耐药性为L858R细胞的12倍。
  • 双突变细胞对来那替尼和波齐替尼仍敏感,IC50分别为4.3和1.3 nM。

核心结论

  • EGFR外显子20 M766Q突变是奥希替尼获得性耐药的新机制。
  • 奥希替尼耐药背景下出现获得性EGFR M766Q突变的EGFR突变肺癌可能对来那替尼和波齐替尼敏感。

研究设计与样本

  • 病例报告:一例79岁女性EGFR L858R/T790M肺腺癌患者三线奥希替尼治疗进展后行循环游离DNA测序。
  • 同源建模研究M766Q对奥希替尼结合的影响。
  • 将L858R和L858R/M766Q突变逆转录病毒导入Ba/F3和NIH/3T3细胞,通过细胞活力和集落形成实验评估对第一代(厄洛替尼)、第二代(阿法替尼、来那替尼、波齐替尼)和第三代(奥希替尼)TKI的敏感性。
  • 通过western blotting检测EGFR介导的信号通路。

主要发现

  • 建模提示EGFR M766Q可能破坏奥希替尼结合。
  • L858R/M766Q双突变细胞对奥希替尼的耐药性为L858R突变细胞的12倍。
  • L858R/M766Q双突变细胞对厄洛替尼和阿法替尼的耐药性为L858R突变细胞的超过250倍。
  • 双突变细胞在临床相关剂量下仍对来那替尼和波齐替尼敏感,抑制50%浓度的浓度分别为4.3和1.3 nM。
  • TKI对集落形成和EGFR信号通路的影响佐证了上述结果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Osimertinib is an effective third-generation tyrosine kinase inhibitor (TKI) for EGFR-mutant lung cancers. However, treatment for patients with acquired resistance to osimertinib remains challenging. We characterized a novel EGFR mutation in exon 20 that was acquired while on osimertinib. METHODS: A 79-year-old woman had disease progression during third-line treatment with osimertinib for an EGFR L858R/T790M-mutant lung cancer. Sequencing of circulating cell-free DNA showed EGFR L858R, an acquired novel EGFR M766Q mutation in exon 20, and no evidence of EGFR T790M. Homology modeling was performed to investigate the effects of M766Q on binding to osimertinib. L858R and L858R/M766Q mutations were retrovirally introduced into Ba/F3 and NIH/3T3 cells and evaluated for sensitivity to first-generation (erlotinib), second-generation (afatinib, neratinib, and poziotinib), and third-generation TKIs (osimertinib) by cell viability and colony-formation assays. EGFR-mediated signaling pathways were interrogated by western blotting. RESULTS: Modeling suggested that EGFR M766Q could disrupt osimertinib binding. L858R/M766Q double-mutant cells were 12-fold more resistant to osimertinib, and more than 250-fold more resistant to erlotinib and afatinib, as compared to L858R-mutant cells. In contrast, double-mutant cells remained sensitive to neratinib and poziotinib at clinically relevant doses (concentration that inhibits 50%, 4.3 and 1.3 nM, respectively). This was corroborated by the effects of the TKIs on colony formation and EGFR signaling. CONCLUSIONS: Acquisition of EGFR M766Q exon 20 mutation is a novel mechanism of acquired resistance to osimertinib. EGFR-mutant lung cancers with an acquired EGFR M766Q mutation in the setting of osimertinib resistance may be sensitive to neratinib and poziotinib.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Castellano GM, Aisner J, Burley SK, et al. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib. J Thorac Oncol. 2019. PMID: 31254668. doi:10.1016/j.jtho.2019.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。